CADL — Candel Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1841387 ·
Last close
$7.95
Market Cap
$582.50M
52W High
$9.27
52W Low
$4.44
ADV30
2,285,968
Next earnings
2026-08-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,262,000 | -8,861,000 | 201,920,000 | 194,834,000 | 63,891,000 |
| Dec 2025 | 0 | — | -15,663,000 | -29,496,000 | 125,195,000 | 119,731,000 | 73,273,000 |
| Sep 2025 | 0 | — | -13,207,000 | -11,269,000 | 93,598,000 | 86,963,000 | 13,474,000 |
| Jun 2025 | 0 | — | -11,177,000 | -4,796,000 | 105,968,000 | 100,687,000 | 15,758,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-38,311,000
Investing CF
$-560,000
Financing CF
$56,098,000
CapEx
$-587,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.71
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-230,387,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-36,063,000
Pretax Income TTM
$-38,182,000
Interest Exp TTM
$2,119,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -48,177,000 | -38,182,000 | 125,195,000 | 73,273,000 | — | -38,311,000 |
| Dec 2024 | 0 | -33,371,000 | -55,177,000 | 106,866,000 | 40,539,000 | — | -27,023,000 |
| Dec 2023 | 0 | -38,391,000 | -37,939,000 | 41,201,000 | 28,456,000 | — | -34,244,000 |
| Dec 2022 | 125,000 | -34,674,000 | -18,794,000 | 77,691,000 | 29,977,000 | — | -31,419,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VALN | Valneva SE | $573.68M | $6.05 | — |
| TECX | Tectonic Therapeutic, Inc. | $565.89M | $29.99 | — |
| CKDXF | Opthea Ltd | $601.91M | $0.44 | — |
| CABA | Cabaletta Bio, Inc. | $606.56M | $3.72 | — |
| AGMB | Agomab Therapeutics NV | $544.19M | $11.05 | — |
News headlines (Yahoo Finance, 1h cache)
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
2026-05-20 15:13 · Yahoo
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
2026-05-19 13:55 · Yahoo
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonge
2026-05-15 20:05 · Yahoo
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-14 12:05 · Yahoo
Candel Therapeutics to Present at Upcoming Investor Conferences
2026-05-13 12:05 · Yahoo
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Asso
2026-05-04 12:05 · Yahoo
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 20:05 · Yahoo
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
2026-04-29 12:36 · Yahoo
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
2026-04-29 12:05 · Yahoo
Candel Therapeutics reports extended survival in Phase 2a lung cancer trial of CAN-2409
2026-03-17 14:35 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.